Prognostic Model Construction and Immune Microenvironment Analysis of Breast Cancer Based on Ferroptosis-Related lncRNAs

References

• Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13:1387–1397. doi:10.7150/ijbs.21635
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. doi:10.1016/S0140-6736(05)66544-0
   PubMed Web of Science ®Google Scholar
• Cao JY, Dixon SJ. Mechanisms of Ferroptosis. Cell Mol Life Sci. 2016;73(11–12):2195–2209. doi:10.1007/s00018-016-2194-1
   PubMed Web of Science ®Google Scholar
• Manz DH, Blanchette NL, Paul BT, Torti FM, Torti SV. Iron and cancer: recent insights. Ann N Y Acad Sci. 2016;1368(1):149–161. doi:10.1111/nyas.13008
   PubMed Web of Science ®Google Scholar
• Hassannia B, Vandenabeele P, Vanden BT. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35(6):830–849. doi:10.1016/j.ccell.2019.04.002
   PubMed Web of Science ®Google Scholar
• Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34. doi:10.1186/s13045-019-0720-y
   PubMed Web of Science ®Google Scholar
• Ma S, Henson ES, Chen Y, Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7(7):e2307. doi:10.1038/cddis.2016.208
   PubMed Web of Science ®Google Scholar
• Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012;482(7385):339–346. doi:10.1038/nature10887
   PubMed Web of Science ®Google Scholar
• Postepska-Igielska AA, Giwojna L, Gasri-Plotnitsky L, Schmitt N, Dold A. lncRNA Khps1 Regulates Expression of the Proto-oncogene SPHK1 via Triplex-Mediated Changes in Chromatin Structure. Mol Cell. 2015;60:626–636. doi:10.1016/j.molcel.2015.10.001
   PubMed Web of Science ®Google Scholar
• Kleaveland B, Shi CY, Stefano J, Bartel DP. A Network of Noncoding Regulatory RNAs Acts in the Mammalian Brain. Cell. 2018;174:350–362.e17. doi:10.1016/j.cell.2018.05.022
   PubMed Web of Science ®Google Scholar
• Zealy RW, Fomin M, Davila S, et al. Long noncoding RNA complementarity and target transcripts abundance. Biochim Biophys Acta GeneRegul Mech. 2018;1861:224–234. doi:10.1016/j.bbagrm.2018.02.001
   PubMed Web of Science ®Google Scholar
• Lopez-Pajares V. Long non-coding RNA regulation of gene expression during differentiation. Pflugers Arch. 2016;468:971–981. doi:10.1007/s00424-016-1809-6
   PubMed Web of Science ®Google Scholar
• Li J, Tian H, Yang J, et al. Long noncoding RNAs regulate cell growth, proliferation and apoptosis. DNA Cell Biol. 2016;35:459–470. doi:10.1089/dna.2015.3187
   PubMed Web of Science ®Google Scholar
• Cai B, Ma W, Bi C, et al. Long noncoding RNA H19 mediates melatonin inhibition of premature senescence of c-kit (+) cardiac progenitor cells by promoting miR-675. J Pineal Res. 2016;61:82–95. doi:10.1111/jpi.12331
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–574. doi:10.1177/0272989X06295361
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–448. doi:10.3322/caac.21412
   PubMed Web of Science ®Google Scholar
• Fang Y, Wang J, Wu F, et al. Long non-coding RNA HOXA-AS2 promotes proliferation and invasion of breast cancer by acting as a miR-520c-3p sponge. Oncotarget. 2017;8:46090–46103. doi:10.18632/oncotarget.17552
   PubMedGoogle Scholar
• Wang M, Mao C, Ouyang L, et al. Long Noncoding RNA LINC00336 Inhibits Ferroptosis in Lung Cancer by Functioning as a Competing Endogenous RNA. Cell Death Differ. 2019a;26(11):2329–2343. doi:10.1038/s41418-019-0304-y
   PubMed Web of Science ®Google Scholar
• Wu X, Liu C, Li Z. Regulation of GSK3β/Nrf2 Signaling Pathway Modulated Erastin-Induced Ferroptosis in Breast Cancer. Mol Cell Biochem. 2020;473(1–2):217–228. doi:10.1007/s11010-020-03821-8
   PubMed Web of Science ®Google Scholar
• Kong X, Duan Y, Sang Y, et al. LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. J Cell Physiol. 2019;234(6):9105–9117. doi:10.1002/jcp.27587
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu S, Zhu X, et al. LncRNA-encoded polypeptide ASRPS inhibits triple-negative breast cancer angiogenesis. J Exp Med. 2020;217(3):e20190950. doi:10.1084/jem.20190950
   Web of Science ®Google Scholar
• Lu D, Yang Z, Xia Q, et al. ACADSB Regulates Ferroptosis and Affects the Migration, Invasion, and Proliferation of Colorectal Cancer Cells. Cell Biol Int. 2020;44(11):2334–2343. doi:10.1002/cbin.11443
   PubMed Web of Science ®Google Scholar
• Brown CW, Amante JJ, Chhoy P, et al. Prominin2 drives ferroptosis resistance by stimulating iron export. Dev Cell. 2019;51(5):575–586. doi:10.1016/j.devcel.2019.10.007
   PubMed Web of Science ®Google Scholar
• Jiang H, Zhang XW, Liao QL, Wu WT. Electrochemical Monitoring of Paclitaxel-Induced ROS Release from Mitochondria inside Single Cells. Small. 2019;15(48):e1901787. doi:10.1002/smll.201901787
   PubMed Web of Science ®Google Scholar
• Vernier M, Dufour CR, McGuirk S, et al. Estrogen-related Receptors Are Targetable ROS Sensors. Genes Dev. 2020;34(7–8):544–559. doi:10.1101/gad.330746.119
   PubMed Web of Science ®Google Scholar
• Song X, Long D. Nrf2 and ferroptosis: a new research direction for 42. neurodegenerative diseases. Front Neurosci. 2020;14:267. doi:10.3389/fnins.2020.00267
   PubMed Web of Science ®Google Scholar
• Zhong H, Zeng G, Lang H. Overexpression of the lncRNA AC012213.3 Promotes Proliferation, Migration and Invasion of Breast Cancer via RAD54B/PI3K/AKT Axis and is Associated with Worse Patient Prognosis. Cancer Manag Res. 2021;13:7213–7223. doi:10.2147/CMAR.S322195
   PubMed Web of Science ®Google Scholar
• Kaiming Z, Liqin P, Tian D, et al. A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Immune Microenvironment for Breast Cancer. Front Mol Biosci. 2021;8:678877. doi:10.3389/fmolb.2021.678877
   PubMed Web of Science ®Google Scholar
• Suarez-Lopez L, Sriram G, Kong YW, et al. MK2 contributes to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis. Pro Natl Acad Sci USA. 2018;115:4236–4244. doi:10.1073/pnas.1722020115
   PubMed Web of Science ®Google Scholar
• Wing JB, Tanaka A, Sakaguchi S. Human FOXP 3+ regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50:302–316. doi:10.1016/j.immuni.2019.01.020
   PubMed Web of Science ®Google Scholar
• Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19:108–119. doi:10.1038/s41590-017-0022-x
   PubMed Web of Science ®Google Scholar
• Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the Crossroads of Cancer-Acquired Drug Resistance and Immune Evasion. Nat Rev Cancer. 2019;19(7):405–414. doi:10.1038/s41568-019-0149-1
   PubMed Web of Science ®Google Scholar
• Wang W, Green M, Choi JE, et al. CD8+ T Cells Regulate Tumour Ferroptosis during Cancer Immunotherapy. Nature. 2019b;569(7755):270–274. doi:10.1038/s41586-019-1170-y
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang Y, Xia S, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579:415–420. doi:10.1038/s41586-020-2071-9
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang Y, Ding J, et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579:421–426. doi:10.1038/s41586-020-2079-1
   PubMed Web of Science ®Google Scholar
• Lang X, Green MD. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9:1673–1685. doi:10.1158/2159-8290.CD-19-0338
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998. doi:10.1038/ni1102-991
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532. doi:10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330. doi:10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Tobin NP, Harrell JC, Lovrot J, et al. The molecular subtype and tumor characteristics of breast cancer metastases significantly influence patient post-relapse survival. Ann Oncol. 2015;26:81–88. doi:10.1093/annonc/mdu498
   PubMed Web of Science ®Google Scholar
• Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167:671–686. doi:10.1007/s10549-017-4537-5
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460. doi:10.1200/JCO.2015.64.8931
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172
   PubMed Web of Science ®Google Scholar
• Nolan E, Savas P, Policheni AN, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. 2017;9(393):eaal4922. doi:10.1126/scitranslmed.aal4922
   PubMed Web of Science ®Google Scholar
• Kok M, Voorwerk L, Horlings H, et al. Adaptive Phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): final response data stage I and first translational data. JCO;2018. 1012. doi:10.1200/JCO.2018.36.15_suppl.1012
   Google Scholar
• McCann KE, Hurvitz SA. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context. 2018;7:212540. doi:10.7573/dic.212540
   PubMedGoogle Scholar
• Hu ZI, Ho AY, McArthur HL. Combined radiation therapy and immune checkpoint blockade therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2017;99(1):153–164. doi:10.1016/j.ijrobp.2017.05.029
   PubMed Web of Science ®Google Scholar
• Force J, Holl E, Brown M, et al. Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy. JCO. 2018;36:e12641. doi:10.1200/JCO.2018.36.15_suppl.e12641
   Web of Science ®Google Scholar